Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

The repositioning of epigenetic probes/inhibitors identifies new anti-schistosomal lead compounds and chemotherapeutic targets.

Whatley KCL, Padalino G, Whiteland H, Geyer KK, Hulme BJ, Chalmers IW, Forde-Thomas J, Ferla S, Brancale A, Hoffmann KF.

PLoS Negl Trop Dis. 2019 Nov 15;13(11):e0007693. doi: 10.1371/journal.pntd.0007693. eCollection 2019 Nov.

2.

Delayed endometrial decidualisation in polycystic ovary syndrome; the role of AR-MAGEA11.

Younas K, Quintela M, Thomas S, Garcia-Parra J, Blake L, Whiteland H, Bunkheila A, Francis LW, Margarit L, Gonzalez D, Conlan RS.

J Mol Med (Berl). 2019 Sep;97(9):1315-1327. doi: 10.1007/s00109-019-01809-6. Epub 2019 Jun 29.

3.

Antischistosomal Properties of Sclareol and Its Heck-Coupled Derivatives: Design, Synthesis, Biological Evaluation, and Untargeted Metabolomics.

Crusco A, Whiteland H, Baptista R, Forde-Thomas JE, Beckmann M, Mur LAJ, Nash RJ, Westwell AD, Hoffmann KF.

ACS Infect Dis. 2019 Jul 12;5(7):1188-1199. doi: 10.1021/acsinfecdis.9b00034. Epub 2019 May 28.

PMID:
31083889
4.

An Abies procera-derived tetracyclic triterpene containing a steroid-like nucleus core and a lactone side chain attenuates in vitro survival of both Fasciola hepatica and Schistosoma mansoni.

Whiteland HL, Chakroborty A, Forde-Thomas JE, Crusco A, Cookson A, Hollinshead J, Fenn CA, Bartholomew B, Holdsworth PA, Fisher M, Nash RJ, Hoffmann KF.

Int J Parasitol Drugs Drug Resist. 2018 Dec;8(3):465-474. doi: 10.1016/j.ijpddr.2018.10.009. Epub 2018 Oct 26.

5.

Methyl-CpG-binding (SmMBD2/3) and chromobox (SmCBX) proteins are required for neoblast proliferation and oviposition in the parasitic blood fluke Schistosoma mansoni.

Geyer KK, Munshi SE, Whiteland HL, Fernandez-Fuentes N, Phillips DW, Hoffmann KF.

PLoS Pathog. 2018 Jun 28;14(6):e1007107. doi: 10.1371/journal.ppat.1007107. eCollection 2018 Jun.

6.

Design, synthesis and anthelmintic activity of 7-keto-sempervirol analogues.

Crusco A, Bordoni C, Chakroborty A, Whatley KCL, Whiteland H, Westwell AD, Hoffmann KF.

Eur J Med Chem. 2018 May 25;152:87-100. doi: 10.1016/j.ejmech.2018.04.032. Epub 2018 Apr 17.

7.

A role for STEAP2 in prostate cancer progression.

Whiteland H, Spencer-Harty S, Morgan C, Kynaston H, Thomas DH, Bose P, Fenn N, Lewis P, Jenkins S, Doak SH.

Clin Exp Metastasis. 2014 Dec;31(8):909-20. doi: 10.1007/s10585-014-9679-9. Epub 2014 Sep 24.

PMID:
25248617
8.

Putative prognostic epithelial-to-mesenchymal transition biomarkers for aggressive prostate cancer.

Whiteland H, Spencer-Harty S, Thomas DH, Davies C, Morgan C, Kynaston H, Bose P, Fenn N, Lewis PD, Bodger O, Jenkins S, Doak SH.

Exp Mol Pathol. 2013 Oct;95(2):220-6. doi: 10.1016/j.yexmp.2013.07.010. Epub 2013 Aug 6.

PMID:
23933194
9.

The pharmacokinetics of fentiazac and its metabolite, p-hydroxyfentiazac, after twice-daily oral administration to male volunteers.

Dowell PS, Pierce DM, Franklin RA, Norris R, Harries H, Whiteland H.

Xenobiotica. 1984 Dec;14(12):947-53.

PMID:
6531942

Supplemental Content

Loading ...
Support Center